KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to -$136.7 million.

  • Ionis Pharmaceuticals' Free Cash Flow fell 10.21% to -$136.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.7 million, marking a year-over-year increase of 18.40%. This contributed to the annual value of -$546.2 million for FY2024, which is 64.86% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Free Cash Flow is -$136.7 million, which was down 198.33% from $139.0 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Free Cash Flow registered a high of $201.2 million during Q4 2021, and its lowest value of -$204.3 million during Q4 2022.
  • Over the past 3 years, Ionis Pharmaceuticals' median Free Cash Flow value was -$126.1 million (recorded in 2024), while the average stood at -$94.4 million.
  • In the last 5 years, Ionis Pharmaceuticals' Free Cash Flow plummeted by 520.48% in 2024 and then surged by 210.24% in 2025.
  • Ionis Pharmaceuticals' Free Cash Flow (Quarterly) stood at $201.2 million in 2021, then slumped by 201.57% to -$204.3 million in 2022, then skyrocketed by 116.48% to $33.7 million in 2023, then plummeted by 520.48% to -$141.6 million in 2024, then dropped by 10.21% to -$136.7 million in 2025.
  • Its last three reported values are -$136.7 million in Q3 2025, $139.0 million for Q2 2025, and -$163.4 million during Q1 2025.